Many patients who suffer from medically refractory epilepsy are not candidates for resective brain surgery. Success of deep brain stimulation (DBS) in relieving a significant number of symptoms of various movement disorders paved the way for investigations into this modality for epilepsy. Open-label and small blinded trials have provided promising evidence for the use of DBS in refractory seizures, and the first randomized control trial of DBS of the anterior thalamic nucleus is currently underway.
INTRODUCTION
Despite maximal antiepileptic drug (AED) therapy, more than 30% of patients with epilepsy will suffer from persistent seizures. [1] [2] [3] Resective brain surgery is generally indicated for refractory partial seizures and can provide at least a 90% reduction in seizure frequency 4 ; however, permanent neurologic deficits or death occurs in nearly 4% of cases. 4 Furthermore, up to 40% of patients are not candidates for surgical resection. 5 Vagus nerve stimulation (VNS) as an adjunct to medical therapy is a reasonable option for these patients and is associated with up to a 50% reduction in seizure frequency. 6 Nevertheless, most of these patients will not be seizurefree. Thus, due to the remarkable success of deep brain stimulation (DBS) for movement disorders, 7, 8 combined with its advantages of titratability, reversibility, and low risk of complications, 9, 10 there has been an explosion of research into implantable deep brain devices for treating refractory epilepsy. 11, 12 The mechanism by which DBS may diminish seizures remains largely unknown. The clinical effect of highfrequency DBS, however, appears to mimic precursor ablative procedures. 13 Thus, stimulation-induced disruption of unopposed network activity is one hypothesis that appears to be consistent with available data. 14, 15 Furthermore, DBS at high frequencies may block cortical epileptiform activity. 16 -18 Indeed, the anterior nucleus of the thalamus (ANT) has been lesioned stereotactically, resulting in improved seizure control in humans. 19 DBS of various neural targets has been investigated, including the thalamus, the subthalamic nucleus (STN), cerebellum, hippocampus, caudate nucleus, and mammillary nuclei. 20 -24 Here we will review evidence from animal studies and rare pilot studies in humans of ANT DBS, which is currently being evaluated as a potential target in an ongoing double-blind randomized trial in humans (the SANTE trial: Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy). 25 
DEEP BRAIN STIMULATION OF THE ANTERIOR NUCLEUS OF THE THALAMUS

Rationale
In 1937, James W. Papez 26 described a circuit linking hippocampal output via the fornix and mammillary nuclei to the ANT. Projections from the ANT travel to the cingulum bundle and then around the wall of the lateral ventricle to the parahippocampal cortex, completing the circuit by returning to the hippocampus. Radiologic alterations have been noted in structures within the classic circuit of Papez in mesial temporal sclerosis, as well as other forms of epilepsy. 27 Thus, it is conceivable that DBS of structures within this circuit may result in direct anterograde cortical stimulation. The ANT is an appealing target because of its relatively small size and projections to limbic structures, ultimately affecting wide regions of neocortex. Further, it is not as deep or close to basal vascular structures as are the mammillary nuclei. These anatomic connections and precursor ablative techniques have motivated investigation of ANT DBS for epilepsy.
Animal studies
Seizure suppression with electrical stimulation of deep brain structures has shown promise in animal models. Observations of enhanced glucose metabolism in the ANT after administration of both pentylenetetrazole and ethosuximide to guinea pigs supports the role of the ANT in propagating seizure activity. 28 Bilateral electrolytic lesions of the tracts connecting the mammillary bodies to the ANT result in essentially complete protection from pentylenetetrazol-induced seizure activity. 29 Recently, high-frequency DBS (100 Hz) of the ANT has been shown to increase the seizure threshold in a pentylenetetrazole-induced seizure model. 30 On the other hand, lowfrequency (8 Hz) DBS was proconvulsant, as noted in earlier studies. 18, 31 Bilateral ANT DBS may also prolong the latency of onset of status epilepticus after administration of pilocarpine. 32 Nevertheless, efficacy of ANT DBS for epilepsy in animal models is still debated, given its lack of effect reported from numerous studies, as well as an exacerbation of seizure frequency by chronic ANT DBS.
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Potential indications in humans
Currently there are no widespread indications for DBS in epilepsy, because it is still considered an experimental therapy. For inclusion in the SANTE trial, patients must suffer from partial onset seizures with or without secondary generalization associated with frequent falls, injuries, and impaired quality of life. 34 -37 Seizures should be refractory to 12-18 months of at least two therapeutically dosed antiepileptic agents. In the future, however, a failure to respond to surgical resection or vagal nerve stimulation may also be indications for DBS. Scalp video-EEG monitoring is necessary to characterize seizures and demonstrate bilateral or nonlocalizing findings consistent with preoperative imaging. The subject, family, or legal guardian must be capable of recognizing seizures and maintaining a seizure diary.
ANT targeting
At our center, general endotracheal anesthesia or local anesthesia is administered before placement of the stereotactic frame. 38 Frame tilt should be parallel to the lateral canthal-external auditory meatal line, which is itself approximately parallel to the anterior commissureposterior commissure (AC-PC) line. After attachment of the magnetic resonance imaging (MRI) localizer, an MRI is obtained with both fast spin echo inversion recovery and standard T2 images. 34 -37 Computed tomography (CT) may be a reasonable alternative to MRI for stereotactic localization of the ANT. 34 Target sites are selected from MRI by using 1-mm thick-axial, coronal, and sagittal spoiled gradient echo pulse sequences. Indirect localization of the ANT is performed with reference to a standard stereotactic atlas 40 by identifying the AC-PC line on the sagittal image. AC and PC coordinates relative to the center of the frame are obtained to calculate the midcommissural point. The ANT is 5 mm lateral and 12 mm superior to the midcommissural point. 40 Direct visualization of the ANT is also possible. We download the imaging data to a surgical navigation system (Medtronic Stealth navigation; Medtronic, Minneapolis, MN; Stryker Leibinger, Kalamazoo, MI), to perform simulation of the planned trajectory from the entry point to the ANT, to confirm avoidance of sulcal vessels (FIG. 1) . Because of the location of the ANT, the lateral ventricle is invariably traversed.
Surgical procedure
The patient is placed in a supine or semisitting position. 34 -39 After Mayfield fixation, sterile preparation of the unshaven head, and local infiltration with 1% lidocaine 1:100,000 epinephrine, an incision is made overlying the coronal suture. A burr hole is placed, and the dura and pia are sharply incised and cauterized. A guide cannula is inserted and advanced deep into the brain to a point 10 mm from the desired target under direct fluoroscopic and Leksell frame guidance. Under local anesthesia, a monopolar single-unit recording electrode (Advanced Research Systems, Atlanta, GA, or FHC, Bowdoinham, ME) can be introduced to confirm anatomic depth for entry into thalamic tissue after traversing the lateral ventricle. 35 No units are recorded while traversing the lateral ventricle. The electrode tip is advanced until recordings are first heard (ANT superficial surface), then until units cease (intralaminar region) and then recommence (dorsomedian nucleus of the thalamus). Extracellular action potentials are amplified with a GS3000 (Axon Instruments, Sunnyvale, CA) or Leadpoint (Medtronic) amplifier and simultaneously recorded using standard recording techniques (300 -10,000 Hz), together with a descriptive voice channel. ANT neurons are identified based on 1) regional characteristics, 2) a firing rate previously described for human recordings, 35 and 3) a characteristic burst firing pattern.
After removing the single-unit recording electrode, a stimulation lead (Radionics stimulation/lesioning probe; Integra Radionics, Burlington, MA) is introduced to elicit the driving response suggestive of ANT placement with a stimulation frequency of 5 to 10 cycles/s, pulse width at 90 -330 s, pulse amplitude at 4 -5 V, and total pulse durations between 3 and 10 s (FIG. 2) .
ANT DBS has been associated with recruiting rhythms on cortical EEG in patients with the most pronounced seizure frequency reduction. 36 These changes in EEG signal morphology can, however, be elicited from several other thalamic nuclei. 31 Furthermore, a recent report indicated that these recruiting rhythms induced by lowfrequency ANT DBS may reflect mixed activation of both specific and nonspecific thalamocortical pathways, and thus not serve as a physiologic verification of optimal localization. 41 Once this lead has been removed, the DBS lead is advanced to the ANT, ensuring that all contacts of the lead are within thalamic parenchyma, and the cannula and lead stylet are withdrawn under fluoroscopic guidance. The stimulation leads we use are Medtronic 3387 DBS depth electrodes with 4 platinum-iridium stimulation contacts 1.5 mm wide, with 1.5 mm edge-to-edge separation because the ANT is relatively larger than other DBS targets. Another fluoroscopic image is acquired to show that the electrode is secure. The lead is secured to a burr-hole cap, and the skin incision is closed. The same sequence of steps is performed to place the contralateral electrode. The stereotactic frame is removed.
We elect to place the internal pulse generator (IPG) at the same setting, but it can be placed at a later date. The head, neck, and infraclavicular regions are sterilized in preparation for placement of the IPG (Medtronic model Itrel II, Soletra, or Kinetra) in a subclavicular pocket bilaterally. The scalp incision is reopened for connection of the lead to an extension wire (Medtronic 7495 lead extension), which is tunneled subcutaneously to the IPG or IPGs.
Postoperative management
The site of placement of the DBS leads is confirmed postoperatively by MRI or CT after reversal and recovery from anesthesia (FIG. 3) . 34 -39 Patients are discharged to home 2 days postoperatively, but multiple outpatient visits are usually necessary for optimization of stimulation parameters. Stimulators are turned on at ϳ10 days postoperatively, and initial stimulation parameters are set at a frequency of 90 -130 Hz, pulse width at 60 -90 s, and pulse amplitude at 4 -5 V, and adjusted during subsequent follow-up to maximize clinical benefit based on each individual response and minimize side effects, such as nystagmus, lethargy, and anorexia. 39 The benefits of bipolar versus monopolar stimulation remain to be determined as do cycling versus continuous stimulation. A recent study of bilateral ANT DBS in four patients with refractory epilepsy found no significant difference in seizure frequency between cycling and continuous stimulation period using within-group comparisons. 34 One proposed method of cycling or intermittent stimulation using an open-loop device (discussed below) is through a duty cycle of 1 min on and 5 min off.
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Intermittent stimulation may increase the battery life of the IPG, is theoretically safer for neural tissue than chronic continuous stimulation, and has been successful in clinical trials for VNS for epilepsy.
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Clinical outcome
We are limited at this time to small sample pilot studies evaluating ANT DBS as a treatment for pharmacoresistant seizures. Despite significant individual variation in outcome, bilateral high-frequency ANT DBS appears overall to be safe, well-tolerated, and effective in some subjects with inoperable refractory epilepsy. Table 1 summarizes the results of six pilot studies of ANT DBS.
Upton et al. 42 reported significant reduction in seizure frequency in four of six patients with intractable epilepsy, one of whom was completely seizure-free at follow-up. This may be due to microthalamotomy or lesioning of the ANT. 43 Electrode implantation appears to decrease seizure frequency itself, and activation of the IPG and multiple subsequent adjustments to stimulatory parameters or contacts may not be linked to any further benefits in seizure control. 34, 39 In one patient, however, the IPGs were turned off after 3 years of DBS with maintenance of improved seizure control for more than 1 year. Thus, it is difficult to distinguish the relative effects of electrode insertion and stimulation on the reduction in seizure frequency.
The effect of microthalamotomy on seizure propagation, however, continues to be debated, and a recent study was unable to detect a lesion effect during the immediate postoperative period. 37 Reorganization of brain circuitry with chronic stimulation even in the absence of a histologic lesion may be an alternative explanation for seizure control maintained without ongoing stimulation.
Other studies of intermittent ANT DBS have reported significant reduction in frequency and propagation of generalized tonic-clonic seizures and complex partial seizures in four of five patients. 35 Only one of the five patients exhibited a statistically significant reduction in total seizure frequency, however, and discontinuation of DBS resulted in an immediate increase in seizure frequency and intensity that improved when stimulation was resumed. This suggests that ANT DBS-induced inhibition is at least in part implicated in reducing seizure frequency. 34, 35, 37 The beneficial response to closed-loop stimulation (discussed below) provides further support for a beneficial role of electrical stimulation.
A recent study of long-term follow-up noted that electrode implantation and stimulation of the ANT resulted in a Ͼ50% seizure reduction in five of six patients. However, significant benefit in two patients was not seen until years 5 and 6 with the addition of further adjuvant AEDs. 39 There is evidence for a long-term effect of ANT DBS on the propensity to develop seizures, 39 and indeed, ongoing clinical benefit after cessation of DBS has been noted in tremor. 44 Bitemporal mesial epilepsy, as opposed to extratemporal or poorly localized seizures, 35 ,36,39 may be most responsive to ANT DBS, given a recent report of a Ͼ75% reduction in seizure frequency. 37 Seizure frequency decreased by 93% in one patient, the most dramatic response ever reported. A higher mean frequency (157 Hz) may in part explain such an impressive response.
Complications and adverse effects
ANT DBS appears to be a safe, well-tolerated treatment for refractory epilepsy, with all of the reported complications and stimulation-induced adverse effects being mild and transient. Reported adverse effects due to stimulation are paranoid ideation, nystagmus, auditory hallucinations, anorexia, and lethargy. 39 Complications due to the surgical procedure or hardware include a small right frontal hemorrhage without any permanent neurologic deficit, scalp erosion necessitating removal of the implanted system, infection of the right anterior chest, and accidental turning off of the stimulator. 34, 36, 45 
OTHER ANATOMIC TARGETS FOR DEEP BRAIN STIMULATION FOR EPILEPSY
Other potential targets are worth discussing, to provide a more thorough review of the potential for DBS in epilepsy. Some open-label clinical trials have reported DBS of various targets to treat pharmacoresistant seizures, demonstrating marginal efficacy in stimulating the centromedian nucleus of the thalamus (CMT), caudate nucleus, cerebellum, and STN. 
Centromedian nucleus of the thalamus
As first hypothesized by Penfield, 46 the CMT is an integral part of an ascending subcortical system, arising from the brain stem and diencephalon and projecting diffusely to cerebral cortex, supporting a role for the CMT in the pathophysiology of generalized seizures. 47 The beneficial effect of CMT DBS on seizure control may be due to desynchronization and hyperpolarization of the ascending reticular and cortical neurons. 47 A recent open-label trial in 13 patients with LennoxGastaut syndrome reported overall seizure reduction of 80%, with significant improvement in quality of life. 48 Although CMT DBS may be effective in controlling frequency of generalized seizures, results in patients with complex partial seizures are unclear. 49 -52 In contrast to the results of these open-label studies, a trial of CMT DBS in seven patients using a double-blind, cross-over design, revealed no significant difference in seizure frequency, 53 and a recent report indicated no short-term benefit in two patients, one of whom was subsequently implanted with electrodes in the ANT. 39 
Subthalamic nucleus
Extensive experience of STN DBS for the treatment of Parkinson's disease makes the STN an appealing target. 8 The substantia nigra pars reticulata (SNr) plays a role in seizure propagation through its GABAergic nigrotectal projections to the superior colliculus. 54 Inhibition of GABAergic SNr neurons results in suppression of partial and generalized epileptic seizures in a rat model of epilepsy. 55 The STN exerts excitatory control on the nigral system. Indeed, pharmacological or electrical inhibition of the STN leads to seizure suppression in rats. 20 A case study of high-frequency bilateral STN DBS for a child with inoperable epilepsy due to focal centroparietal dysplasia observed an 81% improvement in seizure frequency at 30 months follow-up. 56 An 80% improvement in two of five patients with partial-onset seizures treated with STN DBS for 16 months has been reported. 57 Another open-label study of STN DBS demonstrated significant improvement of seizures in 4 of 5 patients (mean reduction of seizure frequency 64.2%). 58 Most recently, two cases with refractory partial-onset seizures were treated with bilateral STN DBS. 59 The first patient had a 50% reduction in seizure frequency, but seizure-related injuries continued to occur. The second case noted seizure frequency to be reduced by one-third, but seizures were milder and caused fewer injuries, thus improving the quality of life of this patient. Larger, randomized, double-blind controlled trials are necessary to establish the potential of STN DBS as a treatment for epilepsy.
Caudate nucleus
The head of the caudate nucleus (HCN), thalamus, and neocortex are connected as a functional entity known as the caudate loop. 60 Activation of the HCN is associated with hyperpolarization of cortical neurons, suggesting that suppression of seizure activity may be a result of stimulation-induced inhibition on the cortex. Indeed, low-frequency stimulation (4 -8 Hz) of the ventral part of the HCN has been shown to suppress interictal activity, focal amygdalohippocampal discharges, and generalization of seizures. 61, 62 Controlled clinical studies are necessary to further evaluate the HCN as a target for DBS in epilepsy.
Cerebellum
Cerebellar stimulation (CS) likely activates inhibitory Purkinje cells, resulting in suppression of excitatory cerebellar output to the thalamus and decreased excitatory thalamocortical projections. This ultimately provides inhibition of cortical excitability. 63 In the 1970s, Cooper et al. 64, 65 were the first to report on CS for epilepsy in an open-label trial, demonstrating that 18 of the 34 patients experienced a reduction in seizure frequency of Ն50%. A later long-term study 39 include results from patients included in the study by Hodaie et al. 36 ¶ Multiple changes in stimulation parameters, including continuous vs. cycling were performed in this study. # Four of the six patients had a significant decrease in the frequency of seizures/month (P Ͻ 0.05), but significance for overall mean reduction was not reported. demonstrated that 23 of 32 patients (85%) benefited overall from long-term CS. 66 Controlled, double-blind trials, however, demonstrated improvement in only 2 of 14 patients (14%). 67, 68 A recent double-blind trial of 5 patients demonstrated a significant reduction in generalized tonic-clonic seizures and tonic seizures at 2 years follow-up. 69 Improvement in generalized tonic-clonic seizures occurred sooner, however, and was more significant than that for tonic seizures. Therefore, as suggested in animal studies, CS may act mainly at the supradiencephalic level. 70 Larger clinical trials are necessary to further assess the role of CS in epilepsy treatment.
Hippocampus
Substantial evidence exists to suggest that temporal lobe seizures are both initiated from and propagated through the hippocampus, 71, 72 an integral component of the circuit of Papez. 26, 27, 73 Subacute hippocampal stimulation (HS) using bilateral depth electrodes or unilateral electrode grids abolished complex partial and secondarily generalized tonic-clonic seizures and significantly decreased the number of interictal EEG spikes at the focus in 7 of 10 patients with intractable temporal lobe seizures. 74 A subsequent study of chronic HS by the same group in three patients demonstrated persistently blocked epileptogenesis with no negative effect on shortterm memory. 75 Continuous high-frequency HS for about 2 weeks in 10 patients revealed a significant decrease in seizures and interictal paroxysmal activity. 75 A small open series of three patients with complex partial seizures reported that DBS of the amygdalohippocampal region resulted in a Ͼ50% reduction in seizure frequency at 5 months follow-up. 76 More recently, these investigators reported that at a mean follow up of 14 months, bilateral amygdalohippocampal DBS in seven patients resulted in one patient who was free of complex partial seizures. 77 Three other patients had more than a 50% reduction in seizure frequency, and two of the seven patients had a reduction of 25%. Only one patient had no change in seizure frequency. Controlled studies with larger sample sizes are mandatory to identify a potential treatment population for HS and optimal stimulation parameters.
OPEN-VERSUS CLOSED-LOOP SYSTEMS
Closed-loop systems are so-called intelligent brain devices that produce bursts of stimulation in response to physiological changes and are capable of terminating epileptiform activity. 11 These stimulators may provide comparable or even more effective seizure suppression than their blind, open-loop counterparts (described above), which stimulate continuously or intermittently. Furthermore, closed-loop devices are more efficient and should be better tolerated than an open-loop modality because the daily doses of stimulation are lower. 78 Intelligent detection may be less toxic than either intermittent or continuous stimulation. 11 Penfield and Jasper 79 were the first to apply focal electrical stimulation to a human's brain and successfully terminated spontaneous seizures. A research group 80 at the University of Pennsylvania, using EEG recordings in mesial temporal lobe epilepsy, identified a spontaneous progression of changes in brain activity that can lead to a full-blown convulsive seizure. These changes can last up to 7 hours prior to the seizure, and, if detected, can be successfully suppressed by an implanted stimulator. Mapping cortical networks involved in seizure generation and determining the most effective time of stimulation relative to seizure onset still require further investigation.
A trial of four patients with refractory seizures treated with responsive cortical stimulation noted suppression of clinical seizures and resolution of electrographic seizure activity. 81 Recently, high-frequency stimulation was performed in eight patients, using a closed-loop system in which stimulation was delivered either to the epileptogenic cortex (n ϭ 4) or the ANT (n ϭ 4) after automated seizure detection. 82 Three of the four cortical stimulation patients and two of the four ANT DBS patients responded with decreased seizure frequency.
A multi-institutional clinical trial of a cranially implanted responsive neurostimulator (RNS; NeuroPace, Mountain View, CA) is currently underway in patients with pharmacoresistant partial onset seizures. 83 The RNS IPG continuously analyzes the patient's electrocortigram and triggers stimulation whenever the characteristics programmed by the clinician are indicative of seizures or epileptiform precursors. A feasibility study of this closedloop device has already described a decrease of ϳ45% in seizure frequency in the majority of patients at 9 months follow-up. 84 
CONCLUSION
Many patients suffering from medically refractory epilepsy are not candidates for resective brain surgery. Some of these patients may benefit from DBS. There are many potential targets for DBS in epilepsy, but current evidence is limited to open-label pilot studies and very small double-blind clinical trials. Although a prospective double-blind randomized trial for ANT DBS is currently ongoing, 25 it is difficult to make any definitive judgments about the efficacy of ANT DBS for seizure control. Further work is also necessary to identify a potential patient population for whom this technique would be indicated, which target is most efficacious, optimal stimulation parameters, and the ideal mode of stimulation.
